Egypt at a glance
- Population
- 118.4 million 2025
- Life expectancy at birth
- 71.8 years, 2024
- People aged 65 and over
- 5.3 % of people, 2025
- Health spending per person
- 141 US$ per person, 2023
- Doctors
- 0.67 per 1,000 people, 2020
Updated
Reviewed by Chandani Patel
Egypt KRAS Inhibitors Market Industry Trends and Forecast to 2034: Segmented by (Target, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$48.1 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $2.3 Mn | — | — |
| 2025 (base) | $3.2 Mn | +$0.8 Mn | — |
| 2026 (forecast) | $4.3 Mn | +$1.1 Mn | +36.3% |
| 2027 (forecast) | $5.9 Mn | +$1.6 Mn | +85.8% |
| 2028 (forecast) | $8.0 Mn | +$2.1 Mn | +153.2% |
| 2029 (forecast) | $10.9 Mn | +$2.9 Mn | +245.1% |
| 2030 (forecast) | $14.9 Mn | +$4.0 Mn | +370.4% |
| 2031 (forecast) | $20.2 Mn | +$5.4 Mn | +541.2% |
| 2032 (forecast) | $27.6 Mn | +$7.4 Mn | +773.9% |
| 2033 (forecast) | $37.6 Mn | +$10.0 Mn | +1,091.2% |
| 2034 (forecast) | $51.3 Mn | +$13.7 Mn | +1,523.5% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $3.2 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $51.3 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 36.3% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Target, indication and end user (see all) |
| Key players | Amgen Inc., Bristol-Myers Squibb, Eli Lilly and Company, Revolution Medicines, Novartis AG (see all) |
| Regulator in Egypt | EDASource: Egyptian Drug Authority. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
KRAS inhibitors target a common cancer-causing gene mutation that was long thought impossible to drug, mainly in lung and bowel cancers.
Key segments of the KRAS Inhibitors market include target (KRAS G12C, KRAS G12D and Pan-KRAS) and indication (Non-Small Cell Lung Cancer, Colorectal Cancer and Pancreatic Cancer).
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the KRAS Inhibitors market. Faster approvals and new combinations are improving survival.
Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the KRAS Inhibitors market.
High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the KRAS Inhibitors market, especially in low- and middle-income countries.
The KRAS Inhibitors market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medicines are registered with the Egyptian Drug Authority (EDA), set up in 2019.[1] A universal health insurance system, set up by Law No. 2 of 2018, is being rolled out governorate by governorate, starting with Port Said in 2019.[2]
[1] Egyptian Drug Authority. Checked 14 Nov 2026.
[2] Universal Health Insurance Authority. Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for KRAS Inhibitors. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Egypt.
What doctors and scientists are doing in KRAS Inhibitors right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 16 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.
From our blog
Egypt · 2 shared keywords
Egypt · 1 shared keyword
Egypt · 1 shared keyword
Egypt
Egypt
Egypt
Digital Health · Egypt
Healthcare Services · Egypt
Healthcare Services · Egypt
Healthcare Services · Egypt
Public Health · Egypt
Medical Devices · Egypt